Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 12:8:603354.
doi: 10.3389/fcvm.2021.603354. eCollection 2021.

Physical Exercise in Managing Takayasu Arteritis Patients Complicated With Cardiovascular Diseases

Yaxin Zhou  1 , Yuan Feng  2 , Wei Zhang  3 , Hongxia Li  1   4 , Kui Zhang  1 , Zhenbiao Wu  1
Affiliations
Review

Physical Exercise in Managing Takayasu Arteritis Patients Complicated With Cardiovascular Diseases

Yaxin Zhou et al. Front Cardiovasc Med. .

Abstract

Takayasu arteritis (TA) is a kind of large-vessel vasculitis that mainly affects the aorta and its branches, and the patients are usually women at a relatively young age. The chronic inflammation of arteries in TA patients leads to stenosis, occlusion, dilatation, or aneurysm formation. Patients with TA thereby have a high risk of cardiovascular disease (CVD) complications, which are the most common cause of mortality. This review summarizes the main cardiovascular complications and the risk factors of cardiovascular complications in patients with TA. Here, we discuss the benefits and potential risks of physical exercise in patients with TA and give recommendations about exercise prescription for TA patients to decrease the risks of CVD and facilitate rehabilitation of cardiovascular complications, which might maximally improve the outcomes.

Keywords: Takayasu arteritis; cardiac diseases; exercise prescription; large-vessel vasculitis; physical exercise.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The vascular complications of TA patients.
Figure 2
Figure 2
The 2018 EULAR recommendation for pharmacological treatment of Takayasu arteritis (TA) (24). csDMARD, conventional synthetic disease-modifying antirheumatic drug; GC, glucocorticoids; TNF, tumor necrosis factor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. . Takayasu arteritis. Ann Intern Med. (1994) 120:919–29. 10.7326/0003-4819-120-11-199406010-00004 - DOI - PubMed
    1. Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, et al. . Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation. (2017) 136:1114–22. 10.1161/CIRCULATIONAHA.116.027094 - DOI - PubMed
    1. Rav-Acha M, Plot L, Peled N, Amital H. Coronary involvement in Takayasu's arteritis. Autoimmun Rev. (2007) 6:566–71. 10.1016/j.autrev.2007.04.001 - DOI - PubMed
    1. Soto ME, Espinola-Zavaleta N, Ramirez-Quito O, Reyes PA. Echocardiographic follow-up of patients with Takayasu's arteritis: five-year survival. Echocardiography. (2006) 23:353–60. 10.1111/j.1540-8175.2006.00238.x - DOI - PubMed
    1. Kotake T, Sueyoshi E, Sakamoto I, Izumida S. Myocarditis associated with Takayasu arteritis. Eur Heart J. (2015) 36:2564. 10.1093/eurheartj/ehv169 - DOI - PubMed

LinkOut - more resources